Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ·Healthcare·Biotechnology
$62.04
+1.83%
Mkt Cap $2.62B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 23, 2026 | $144.57M | $151.67M | +4.91% | -$0.10 | -$0.20 | -94.17% | — | — |
| Q4 2025 Nov 4, 2025 | $144.64M | $118.70M | -17.93% | -$0.35 | -$0.30 | +14.29% | — | — |
| Q3 2025 Aug 6, 2025 | $113.05M | $102.66M | -9.19% | -$0.33 | -$0.48 | -45.45% | — | — |
| Q2 2025 May 1, 2025 | $99.11M | $78.33M | -20.97% | -$0.69 | -$0.64 | +7.25% | — | — |
| Q1 2025 Feb 25, 2025 | $64.45M | $66.41M | +3.04% | -$0.68 | -$0.60 | +11.76% | — | — |
| Q4 2024 Nov 13, 2024 | $43.18M | $48.12M | +11.43% | -$0.94 | -$0.61 | +35.09% | — | — |
| Q3 2024 Aug 8, 2024 | $31.66M | $40.81M | +28.91% | -$0.98 | -$0.88 | +10.20% | — | — |
| Q2 2024 May 8, 2024 | $17.46M | $27.61M | +58.16% | -$1.15 | -$1.01 | +12.17% | — | — |
| Q1 2024 Feb 27, 2024 | $5.66M | $13.08M | +131.02% | -$1.37 | -$1.31 | +4.38% | — | — |
| Q4 2023 Nov 9, 2023 | $5.94M | $1.87M | -68.50% | -$1.40 | -$1.28 | +8.57% | — | — |
| Q3 2023 Aug 10, 2023 | $1.76M | $15.28M | +768.01% | -$1.08 | -$1.17 | -8.33% | — | — |
| Q2 2023 May 9, 2023 | $3.12M | $2.50M | -19.87% | -$0.95 | -$0.88 | +7.37% | — | — |
| Q1 2023 Mar 13, 2023 | $10.00M | $10.00M | +0.00% | -$0.97 | -$0.49 | +49.48% | — | — |
| Q4 2022 Nov 9, 2022 | $3.50M | — | — | -$0.98 | -$0.84 | +14.29% | — | — |
| Q3 2022 Aug 11, 2022 | $11.25M | $15.28M | +35.80% | -$0.65 | -$0.24 | +63.08% | — | — |
| Q2 2022 May 10, 2022 | $5.20M | $539.00K | -89.63% | -$0.87 | -$0.98 | -12.64% | — | — |
| Q1 2022 Mar 14, 2022 | $1.87M | $338.00K | -81.89% | -$0.77 | -$0.72 | +6.49% | — | — |
| Q4 2021 Nov 9, 2021 | $5.33M | $1.24M | -76.74% | -$0.65 | -$0.76 | -16.92% | — | — |
| Q3 2021 Aug 4, 2021 | $22.02M | $22.02M | +0.00% | -$0.48 | $0.33 | +168.75% | — | — |
| Q2 2021 May 11, 2021 | $82.27M | $33.43M | -59.37% | -$0.64 | $0.47 | +173.44% | — | — |